Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Gastroenterol Hepatol ; 31(1): 67-74, 2019 01.
Article in English | MEDLINE | ID: mdl-30239347

ABSTRACT

BACKGROUND: Direct-acting antivirals (DAAs) lead to a high rate of sustained virologic response (SVR) in chronic hepatitis C infection. The aim was to evaluate liver stiffness kinetics, using acoustic radiation force impulse (ARFI) imaging elastography, during and after DAAs in patients who had reached SVR. PATIENTS AND METHODS: A total of 275 consecutive chronic hepatitis C virus-infected patients were included in this longitudinal prospective single-centre study. All patients received DAAs for 8 to 24 weeks, and liver stiffness measurements (LSMs) by ARFI at baseline, at week 4, week 12, week 24, and 24 weeks (SVR24) and 48 weeks (FU48) after the end of treatment were recorded. Transient elastography was performed at baseline and at SVR24. RESULTS: A decrease in LSM was detected at SVR24 by ARFI and transient elastography (P<0.001 and <0.001, respectively). A continuous gradual decrease in ARFI was observed in patients with cirrhosis versus a nonsignificant change in patients without cirrhosis until FU48 (P<0.001 vs. 0.877, respectively). At SVR24, higher baseline ARFI values (P=0.038) were associated with a decrease in LSM in patients with cirrhosis versus normal international normalization ratio (P=0.003), lower bilirubin (P=0.003), and higher albumin (P=0.007) in patients without cirrhosis. The incidence of liver stiffness decrease from baseline was higher in patients with cirrhosis than in those without cirrhosis (P<0.001), whereas the incidence of liver stiffness progression was more pronounced in advanced than in compensated cirrhosis (P<0.001). CONCLUSION: After DAAs in patients with SVR, liver stiffness improves in patients with cirrhosis, whereas non-cirrhotic patients show no true change in liver stiffness. Liver stiffness worsens in patients with advanced liver disease.


Subject(s)
Antiviral Agents/therapeutic use , Elasticity Imaging Techniques , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/drug therapy , Liver/drug effects , Adult , Aged , Aged, 80 and over , Antiviral Agents/adverse effects , Biomarkers/blood , Disease Progression , Drug Therapy, Combination , Female , Germany , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/diagnostic imaging , Hepatitis C, Chronic/virology , Humans , Kinetics , Liver/diagnostic imaging , Liver/metabolism , Liver/virology , Liver Cirrhosis/blood , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/virology , Liver Function Tests , Longitudinal Studies , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Sustained Virologic Response , Treatment Outcome
2.
Liver Int ; 35(7): 1845-52, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25556625

ABSTRACT

BACKGROUND & AIMS: Several real world data demonstrated that eligibility for and tolerability of triple therapy against hepatitis C virus (HCV) infection with a first-wave protease inhibitor is limited. With the approval of sofosbuvir (SOF) effective treatment with and without pegylated interferon (PEG-IFN) has become available for most genotypes. However, no data are available regarding the added benefit of an interferon-free treatment concerning eligibility and tolerability in a real-world scenario. We aimed to assess the eligibility and safety of SOF based therapies in patients with primarily advanced cirrhosis, including decompensated cirrhosis, in a real-world setting. RESULTS: In total, 207 patients were evaluated for a SOF based treatment with and without PEG-IFN. Twenty-six patients did not receive treatment because of safety reasons. Common causes were severe concomitant cardiac disease and advanced renal disease. Autoimmune disease, thrombopaenia, anaemia or hepatic dysfunction did not preclude treatment. Eighty-four patients started treatment, 15 with decompensated cirrhosis. During the first 12 weeks hospitalization occurred in 11 patients most frequently because of typical complications of advanced liver disease. Risk factors for hospitalization were low platelet count and deteriorated liver function. Overall, 982 of 1008 planned treatment weeks (97%) were successfully completed within the first 12 weeks of therapy. CONCLUSION: With the better safety profile of interferon-free therapies, eligibility for HCV treatment will expand broadly, including patients with decompensated cirrhosis. Current limitations are renal failure and concomitant cardiac disease. Patients with advanced cirrhosis still have a high risk for hospitalization even with interferon-free therapies, but can continue HCV treatment in most cases.


Subject(s)
Antiviral Agents/therapeutic use , Eligibility Determination , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Sofosbuvir/therapeutic use , Aged , Antiviral Agents/adverse effects , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/diagnosis , Hospitalization , Humans , Interferon-alpha/therapeutic use , Male , Middle Aged , Patient Selection , Polyethylene Glycols/therapeutic use , Prospective Studies , Ribavirin/therapeutic use , Risk Factors , Sofosbuvir/adverse effects , Time Factors , Treatment Outcome
3.
Dig Liver Dis ; 43(6): 491-7, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21439919

ABSTRACT

BACKGROUND: Transient elastography is increasingly used for assessment of liver fibrosis. Acoustic radiation force impulse imaging (ARFI) is a new technology to perform liver elastography. AIMS: We evaluated the clinical feasibility, validity and accuracy of the ARFI method and compared it to Fibroscan(®) and liver histology. METHODS: Ultrasonographic elastography of the liver using ARFI was performed in 29 patients with liver cirrhosis, 70 patients with liver disease and 23 healthy controls. RESULTS: ARFI was feasible in all patients providing a mean propagation velocity of 1.65±0.93 m/s. ARFI results of the right and left liver lobes were comparable (p<0.001). In cirrhotic patients, ARFI gave significantly higher values than in the other patients (p<0.001). Rate of invalid measurements was lower in ARFI than in Fibroscan(®) (p<0.04). Both elastography methods were highly correlated to each other (p<0.001). Furthermore, ARFI correlated to histological grading of liver fibrosis (p<0.001) and to inflammatory activity (p<0.05). Liver steatosis had no statistical influence on ARFI results (p=0.2) in contrast to Fibroscan(®) (p<0.05). CONCLUSIONS: The new ultrasonographic method of ARFI elastography allows valid, accurate and flexible evaluation of liver stiffness. It seems more feasible in patients with liver cirrhosis than Fibroscan(®). ARFI elastography of the left liver lobe is also possible. Liver steatosis does not seem to influence ARFI elastography.


Subject(s)
Elasticity Imaging Techniques/methods , Liver Cirrhosis/diagnostic imaging , Liver/diagnostic imaging , Adult , Biopsy, Needle , Feasibility Studies , Female , Humans , Liver/metabolism , Liver/pathology , Liver Cirrhosis/metabolism , Liver Cirrhosis/pathology , Liver Diseases/diagnostic imaging , Liver Diseases/pathology , Liver Function Tests , Male , Middle Aged , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...